353 related articles for article (PubMed ID: 29991320)
1. Non-insulin pharmacological therapies for treating type 1 diabetes.
Frandsen CS; Dejgaard TF; Madsbad S; Holst JJ
Expert Opin Pharmacother; 2018 Jun; 19(9):947-960. PubMed ID: 29991320
[TBL] [Abstract][Full Text] [Related]
2. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
3. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Frandsen CS; Dejgaard TF; Madsbad S
Lancet Diabetes Endocrinol; 2016 Sep; 4(9):766-780. PubMed ID: 26969516
[TBL] [Abstract][Full Text] [Related]
4. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
5. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
[TBL] [Abstract][Full Text] [Related]
6. Use of non-insulin therapies for type 1 diabetes.
Garg SK; Michels AW; Shah VN
Diabetes Technol Ther; 2013 Nov; 15(11):901-8. PubMed ID: 24131372
[No Abstract] [Full Text] [Related]
7. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
DeGeeter M; Williamson B
J Pharm Pract; 2016 Apr; 29(2):144-59. PubMed ID: 25312263
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological management of type 2 diabetes mellitus: an update.
El-Kaissi S; Sherbeeni S
Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
[TBL] [Abstract][Full Text] [Related]
9. Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients.
Naciu AM; Pozzilli P
Expert Opin Pharmacother; 2018 Mar; 19(4):355-364. PubMed ID: 29460641
[TBL] [Abstract][Full Text] [Related]
10. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
11. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
Elian V; Popovici V; Karampelas O; Pircalabioru GG; Radulian G; Musat M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396657
[TBL] [Abstract][Full Text] [Related]
12. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Takahashi M; Shibasaki M; Echizen H; Kushiyama A
PLoS One; 2020; 15(7):e0236603. PubMed ID: 32706828
[TBL] [Abstract][Full Text] [Related]
13. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Thompson PL; Davis TME
Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
[TBL] [Abstract][Full Text] [Related]
16. Drugs for type 2 diabetes.
Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
18. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Hermansen K; Mortensen LS
Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
[TBL] [Abstract][Full Text] [Related]
19. The impact of diabetes and diabetes medications on bone health.
Gilbert MP; Pratley RE
Endocr Rev; 2015 Apr; 36(2):194-213. PubMed ID: 25738213
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes.
Tosur M; Redondo MJ; Lyons SK
Curr Diab Rep; 2018 Aug; 18(10):79. PubMed ID: 30116997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
